
Is active with an Italian company for the use of Allergenius 2.0, an expert system for the interpretation of results of the allergic profile obtained from ALEX, a IVD produced by MADx, Wien.
Phenomix, at present, has the expertise for supporting research and development programs for pharma or IVD industries. This support includes the basic technologies, the specific methodologies, the quality control strategies and the interpretation tools.
Expert systems for the support of medical diagnosis remains in the aims of Phenomix that is also involved in other activities:
Phenomix has recently developed the new version of Allergenius, the expert system that was firstly published in 2014.
The first version of Allergenius was built for the interpretation of ImmunoCAP ISAC, the Thermofisher allergens microarray containing 112 components,
that significantly improved the Molecular Based Allergy Diagnostics (MAD) more than 10 years ago. When in 2017, MADx, an Austrian company, developed ALEX,
Phenomix developed the Allergenius version for ALEX.
ALEX is characterized by the presence of 282 allergens (of which, 157 are allergen extracts and 125 are molecular components)
and it is suitable for the description of an extended IgE profile, including inhalants, food, hymenoptera venoms and latex. ALEX excellent features have been recently validated in real life
(Heffler et al, WAOJ, 2018).
The presence of both allergens and relevant component onto the same chip allows for example, the immediate identification of genuine sensitizations and of the presence of IgE
specific for potentially dangerous components. By the use of specific algorithm, Allergenius suggests the use of specific Allergen ImmunoTherapy
(AIT, the so called vaccine for allergies) on the basis of the patient’s IgE profile.

Via Brignole de Ferrari 11
16125 Genova
Italy